Lennox-Gastaut syndrome (LGS) is a severe form of childhood epilepsy characterized by a triad of diagnostic features: polymorphic seizures, diffuse slow bursts-slow waves on the electroencephalogram, and cognitive impairment. The disease belongs to the category of drug-resistant epileptic encephalopathies and usually manifests between the ages of 1 and 8 years, most often between 3 and 5 years of life. The pathology is characterized by a progressive course with the formation of stable resistance to anticonvulsant therapy and pronounced neurological dysfunction.
History of the disease and interesting historical facts
The term "Lennox-Gastaut syndrome" was first introduced into medical practice in 1966 by American neurologists William G. Lennox and Jean Aicardi Gastaut. According to historical data, the first description of similar clinical manifestations was made in 1939 by Gibbs, who noted a specific EEG pattern in children with epilepsy. An interesting fact is that the disease was initially considered a variant of childhood absence epilepsy, but subsequent studies revealed its independent nosological form. In the 1970s, thanks to the development of neurophysiological diagnostic methods, characteristic EEG patterns were established, which made it possible to clearly differentiate LGS from other epileptic syndromes.
Epidemiology
According to modern epidemiological studies, the prevalence of Lennox-Gastaut syndrome is 0.1-0.2% among all forms of epilepsy and about 1-2% among childhood epileptic encephalopathies. Among patients with childhood epilepsy, the incidence of LGS varies between 0.5-1%. The incidence ratio between boys and girls is approximately 1.4:1. The highest risk of developing the syndrome is observed in children aged 1 to 5 years. According to a 2020 meta-analysis including data from 15 countries, the average annual incidence is 1.2 cases per 100,000 children.
Genetic predisposition to this disease
The genetic component in the development of LGS is confirmed by numerous studies. The most significant are mutations in the following genes:
- SCN1A – encodes the α1-subunit of the sodium channel
- GABRG2 – participates in the formation of GABA receptors
- STXBP1 – regulates the secretion of neurotransmitters
- CHD2 – plays a role in chromatin remodeling
According to a study published in the journal Epilepsia (2019), “pathogenic mutations are found in 30-40% of LGS patients.” Particular attention is paid to new mutations that arise de novo, which account for up to 60% of all genetic disorders in this syndrome.
Risk factors for the development of this disease
The main risk factors for the development of LGS can be divided into several categories:
- Perinatal complications: hypoxic-ischemic damage to the central nervous system, intrauterine infections
- Cerebral pathologies: congenital anomalies of brain development, previous meningitis/encephalitis
- Toxic effects: exposure to heavy metals, organic solvents
- Neurometabolic disorders: mitochondrial cytopathies, lysosomal storage diseases
It is important to note that according to a study in the Journal of Child Neurology (2021), “in 25% cases, the etiology cannot be determined even with a comprehensive examination.”
Diagnosis of this disease
The diagnosis of LGS is based on a comprehensive assessment of clinical, electrophysiological and neuroimaging data. Key features:
- Polymorphic seizures: atonic, tonic-clonic, absences, focal
- Characteristic EEG pattern: slow bursts of 1.5-2.5 Hz
- Neuroimaging: MRI of the brain to rule out structural abnormalities
- Laboratory tests: blood chemistry, genetic testing
Differential diagnosis includes other epileptic encephalopathies such as Dravet syndrome and myoclonic epilepsy.
Treatment
The therapeutic strategy for LGS includes:
- Pharmacotherapy: valproate, lamotrigine, topiramate
- Ketogenic diet
- Surgical treatment: vagal stimulation, callosotomy
- Rehabilitation measures: neuropsychological correction
It is important to note the limited effectiveness of standard antiepileptic therapy, which requires a search for alternative approaches.
List of drugs used to treat this disease
The main drugs include:
- Valproic acid
- Lamotrigine
- Topiramate
- Rufinamide
- Tslobazam
According to the ILAE recommendations (2020), the choice of drug depends on the type of attacks and individual tolerability.
Disease monitoring
Regular monitoring of patients with LGS includes:
- Monthly monitoring of seizure frequency
- Quarterly EEG monitoring
- Regular biochemical monitoring
- Cognitive assessment every 6 months
The prognosis remains grave: according to statistics, “complete seizure control is achieved in less than 10% patients.”
Age-related features of the disease
Clinical manifestations of LGS vary depending on age:
- Preschool age: tonic seizures predominate
- School age: frequency of focal seizures increases
- Adolescence: development of drug resistance
According to the Pediatric Neurology study (2022), “early onset of the disease (before 3 years) is associated with a more severe course.”
Questions and Answers
- What tests are needed to confirm the diagnosis? To verify the diagnosis, a comprehensive examination is required, including EEG monitoring, MRI of the brain, genetic testing and biochemical blood analysis.
- Is it possible to completely cure the disease? Unfortunately, complete recovery is possible only in isolated cases; the main goal of therapy is to control attacks and improve quality of life.
- How often should you undergo examinations? Quarterly EEG and regular biochemical monitoring are recommended, especially when taking antiepileptic drugs.
Advice from Dr. Oleg Korzhikov
In my many years of practice, I often encounter questions from parents about the treatment of LGS. Here are the main recommendations:
- Start therapy as soon as possible after diagnosis.
- Do not stop the prescribed treatment without consulting your doctor.
- Follow all prescribed examinations regularly
- Pay special attention to rehabilitation measures
“It is important to remember,” emphasizes Dr. Korzhikov, “that timely diagnosis and properly selected therapy can significantly improve the prognosis of the disease.”
